finanzen.net
20.05.2019 15:45
Bewerten
(0)

Global Heart Failure Drugs Market Drivers, Restraints, Opportunities, Trends, and Forecast up to 2025 with Novartis, GSK, AstraZeneca, Bayer, and Pfizer Dominating

DRUCKEN

DUBLIN, May 20, 2019 /PRNewswire/ -- The "Global Heart Failure Drugs Market - Drivers, Restraints, Opportunities, Trends, and Forecast up to 2025" report has been added to ResearchAndMarkets.com's offering.

Global Heart Failure Drugs Market will grow at a CAGR of 9.1% during the forecast period

The market has witnessed good growth in the past few years and is sustaining due to the increasing elderly population and increasing prevalence of cardiovascular diseases.

The growing market trend continues and is one of the progressively accepted markets in many countries worldwide. Heart failure drugs manufacturers are concentrating on the procurement of funds and collaborating with universities to expand their R&D capabilities. Most of the revenue is generated from the leading players in the market with dominant sales from Novartis AG, GlaxoSmithKline PLC, AstraZeneca PLC, Bayer AG, and Pfizer Inc.

According to the author's analysis, North America leads the global heart failure drugs market in 2018 followed by Europe. The US dominates the market owing to the presence of a majority of the heart failure drugs manufacturers in the region. However, the fastest growth rate is anticipated to be in the APAC region due to the presence of large heart failure patient population and the availability of a wide range of drugs.

By Drug Class:

  • ACE Inhibitors
  • Angiotensin Receptor Blockers
  • Beta Blockers
  • Diuretics
  • Others

The diuretics segment occupied the largest share in 2018. The existing guiding principle by the American College of Cardiology and the American Heart Association recommends that diuretics should be directed at doses adequate to attain optimum volume station and release cramming without making an extremely fast drop in intravascular capacity.

By Regions:

  • North America
  • Europe
  • APAC
  • RoW

North America is dominant in the global heart failure drugs market followed by Europe. The Duke University in North Carolina, US in collaboration with National Heart, Lung, Blood Institute (NHLBI) and Yale University is conducting phase III clinical trial TRANSFORM-HF a large-scale, pragmatic, randomized, unblinded clinical effectiveness study comparing torsemide versus furosemide as a treatment for heart failure.

Heart Failure Drugs Market Research Competitive Analysis - The market is growing at a steady rate with a CAGR of 9.1% during the forecast period 2019-2025. Merger and acquisition, product launches, and strategic collaborations are some of the major strategies adopted by market leaders to maintain their leadership position in the market. For example, in February 2019, Amgen, Cytokinetics, and Servier initiated the METEORIC-HF, the second phase III clinical trial of omecamtiv mecarbil in patients with heart failure.

Universities and educational institutions are collaborating with the market players to develop effective drugs for the treatment of heart failure. For instance, Yale University in collaboration with Boehringer Ingelheim is currently conducting a phase II clinical study; a minor pilot proof of concept study to not only prove the existence but also probe the mechanisms that are fundamental for the cardio-renal effects of empagliflozin in patients with heart failure.

Key Vendors:

  • Novartis AG
  • GlaxoSmithKline PLC
  • AstraZeneca PLC
  • Bayer AG
  • Pfizer, Inc.

Key Competitive Facts

Sclnow Biotechnology Co., Ltd. is studying to access the safety and efficiency of human umbilical cord mesenchymal stem cells (hUC-MSC) in treating individuals suffering from heart failure. This treatment is in phase 1/2 currently.
In January 2019, Sanofi and MyoKardia ended their heart disease drug collaboration.

Market Characteristics

Guidelines Summary

Market Dynamics

Drivers

  • Increasing elderly population
  • Increasing incidence of cardiovascular devices across the globe

Restraints

  • Complex drug development process
  • Adverse effects of heart failure drugs

Opportunities

  • Market expansion opportunities in emerging nations
  • Novel heart failure medicines to fill the gap of unmet need in treatment

Vendors Profile

  • Novartis AG
  • GlaxoSmithKline plc
  • Bayer AG
  • Astra Zeneca PLC
  • Pfizer, Inc.

Companies to Watch for

  • Merck & Co
  • Boehringer Ingelheim GMBH
  • Bristol-Myers Squibb
  • Mylan N.V.
  • Sanofi
  • Amgen Inc.

For more information about this report visit https://www.researchandmarkets.com/r/700pf1

Research and Markets also offers Custom Research services providing focused, comprehensive and tailored research.

Media Contact:


Research and Markets
Laura Wood, Senior Manager
press@researchandmarkets.com   

For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900

U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716

Cision View original content:http://www.prnewswire.com/news-releases/global-heart-failure-drugs-market-drivers-restraints-opportunities-trends-and-forecast-up-to-2025-with-novartis-gsk-astrazeneca-bayer-and-pfizer-dominating-300852371.html

SOURCE Research and Markets

Technische Marktanalyse

Wie geht's an der Börse weiter? Setzt sich der Zick-Zack-Kurs fort oder geht es demnächst kräftig nach unten? Am Montag ab 18 Uhr analysiert Achim Matzke die Situation bei Dax, Dow und Co. Jetzt kostenlos anmelden!
Anzeige
Anzeige
Börse Stuttgart Anlegerclub

Die richtige Strategie für die Börsenkrise

Stecken Sie nicht den Sand in den Kopf, sondern kaufen Sie die richtigen Aktien. Erfahren Sie im aktuellen Anlegermagazin mehr über attraktive Qualitätsaktien und zyklische Aktien
Kostenfrei registrieren und lesen!

Heute im Fokus

DAX geht tiefer ins Wochenende -- Wall Street schließt schwächer -- Bechtle dämpft Erwartungen an Umsatzwachstum -- Broadcom, Varta, Autowerte, Rheinmetall im Fokus

CropEnergies etwas zuversichtlicher für Geschäftsjahr. Fiat Chrysler koopiert mit Engie und Enel bei Ladestationen. 1&1 Drillisch-Aktie und United Internet-Aktie von Unsicherheit geplagt. Swiss Re bringt Tochter ReAssure im Juli an Londoner Börse. Huawei: Android-Ersatz könnte "binnen Monaten" kommen. Bayer bleibt bei Glyphosat - Aber Milliarden für Alternativen.

Die 5 beliebtesten Top-Rankings

Das hat sich geändert
Diese Aktien hat George Soros im Depot
Big-Mac-Index
In welchen Ländern kostet der Big Mac wie viel?
Das verdienen Aufsichtsratschefs in DAX-Konzernen
Deutlich unter Vorstandsgehältern
Die Länder mit den größten Goldreserven 2019
Wer lagert das meiste Gold?
Die zehn größten Kapitalvernichter
Hier wurde am meisten Anlegergeld verbrannt
mehr Top Rankings

Umfrage

Sind Sie an einem Investment in die Cannabis-Branche interessiert?

Online Brokerage über finanzen.net

finanzen.net Brokerage
Handeln Sie für nur 5 Euro Orderprovision* pro Trade aus der Informationswelt von finanzen.net!

ETF-Sparplan

Oskar ist der einfache und intelligente ETF-Sparplan. Er übernimmt die ETF-Auswahl, ist steuersmart, transparent und kostengünstig.
Zur klassischen Ansicht wechseln
Kontakt - Impressum - Werben - Pressemehr anzeigen
Top News
Beliebte Suchen
DAX 30
Öl
Euro US-Dollar
Bitcoin
Goldpreis
Meistgesucht
Deutsche Bank AG514000
Microsoft Corp.870747
Scout24 AGA12DM8
Daimler AG710000
Apple Inc.865985
Amazon906866
Wirecard AG747206
NEL ASAA0B733
TeslaA1CX3T
Beyond MeatA2N7XQ
Allianz840400
BMW AG519000
BASFBASF11
Infineon AG623100
E.ON SEENAG99